SavedAdd your journal

Journals / Mustafa Kemal Üniversitesi Tıp Dergisi / 2015 / Cilt: 6 - Sayı: 21

-

Radyoaktif İyot Tedavisi Sonrası Diferansiye Tiroid Kanserlerinin Takibi-The Follow-up of Differentiated Thyroid Cancers After Radioactive Iodine Treatment

Ebuzer Kalender
Füsun Aydoğan
Cem Oruç
Pages
30–37
Publication Date
2015-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the methods used in the follow-up DTC patients after RIT are reported

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Differentiated thyroid cancerc (DTC) which have very good prognosis are the most common endocrine malignancies.
📊
Key Findings & Data:Post-treatment follow-up of these patients exhibits a great importance because of the higher relapse rates and development of distant metastases in some cases.
💡
Conclusion & Impact:In this review, the methods used in the follow-up DTC patients after RIT are reported
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Diferansiye tiroid kanseri · Radyoaktif iyot tedavisi · Takip

Abstract

Differentiated thyroid cancerc (DTC) which have very good prognosis are the most common endocrine malignancies. Radioactive iodine treatment (RIT) applied to selected patients after thyroidectomy is a highly effective treatment method. Post-treatment follow-up of these patients exhibits a great importance because of the higher relapse rates and development of distant metastases in some cases. In this review, the methods used in the follow-up DTC patients after RIT are reported

Özet

Özet: Diferansiye tiroid kanserleri (DTK) çok iyi prognoza sahip en sık görülen endokrin malignitelerdir. Tiroidektomi sonrası seçilen hastalara uygulanan radyoaktif iyot tedavisi (RİT) oldukça etkin bir tedavi yöntemidir. Bu hastalarda tedavi sonrası takipler, nüks oranlarının yüksek olması ve bazı olgularda uzak metastaz gelişmesi nedeniyle büyük önem arzetmektedir. Bu derlemede RİT sonrası DTK’lı hastaların takibinde kullanılan yöntemler anlatılmaktadır.Anahtar Kelimeler: Diferansiye tiroid kanseri, Radyoaktif iyot tedavisi, TakipAbstarct: Differentiated thyroid cancerc (DTC) which have very good prognosis are the most common endocrine malignancies. Radioactive iodine treatment (RIT) applied to selected patients after thyroidectomy is a highly effective treatment method. Post-treatment follow-up of these patients exhibits a great importance because of the higher relapse rates and development of distant metastases in some cases. In this review, the methods used in the follow-up DTC patients after RIT are reported.Key Words:Giriş: Differentiated thyroid cancer, Radioactive iodine treatment, Follow-up.

🔖

Cite This Article

Kalender, E., Aydoğan, F., Oruç, C. (2015). -. Mustafa Kemal Üniversitesi Tıp Dergisi, Cilt: 6 - Sayı: 21, 30–37. https://ajindex.com/articles/692891

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Referanslar: Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853–78.
  2. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093–7.
  3. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.
  4. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–9.
  5. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.
  6. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:313–9.
  7. Schlumberger MJ, Filetti S, Hay ID. Non toxic goiter and thyroid neoplasia. In: Larsen RP, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams’ textbook of endocrinology. 10th ed. Philadelphia: WB Saunders Company. 2003;457–90.
  8. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191-7.
  9. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.
  10. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.
  11. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001; 86:4092-7.
  12. Kalender E, Elboga U,